Join
Live feed
·
PRReleasevia Quantisnow
AnaptysBio Inc. logo

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

ByQuantisnow·Wall Street's wire, on your screen.
ANAB· AnaptysBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANAB (AnaptysBio Inc.) and more on Quantisnow.